Hamburg, Germany - 05 October 2015: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced it has entered into a multi-year compound management agreement with the U.S. National Cancer Institute ("NCI"), Department of Health and Human Services. Under the terms of the agreement, Evotec will provide compound management services to the NCI Chemical Biology Consortium ("CBC") for a period of five years with a total estimated value of up to EUR 4.5 m ($ 4.9 m).
The NCI Chemical Biology Consortium contract will continue to provide to acquire, store, maintain and distribute the current library collection. This repository will form part of the CBC's drug discovery and development platform for new oncology therapeutics being researched by a consortium of primarily academic and non-profit institutions.
Dr Mario Polywka, Chief Operating Officer of Evotec, commented: "We are pleased the NCI has elected to award Evotec this important contract to support the Chemical Biology Consortium, an important initiative in the discovery of new cancer treatments."
ABOUT THE NCI CHEMICAL BIOLOGY CONSORTIUM (CBC)
The NCI Chemical Biology Consortium ("CBC") was established in 2009 to facilitate the discovery and development of new agents to treat cancer. The Consortium brings together chemical biologists and molecular oncologists from government, industry and academia to address unmet needs in therapeutic oncology. Through the CBC and the interactions among the various participants, the NCI's drug discovery and development pipeline now spans from target identification through proof-of-concept clinical trials. The project is funded in whole with U.S. Federal funds from the National Institutes of Health, Department of Health and Human Services, under contract HHSN261201500010I with Evotec (US), Inc.
Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone: +49.(0)40.56081-255, email@example.com
FORWARD LOOKING STATEMENTS
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.